LXE 408
Alternative Names: LXE-408Latest Information Update: 03 Jun 2025
At a glance
- Originator Novartis
- Developer Drugs for Neglected Diseases Initiative Foundation; Novartis
- Class Amides; Antiparasitics; Antiprotozoals; Fluorobenzenes; Oxazoles; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chagas disease; Visceral leishmaniasis
Most Recent Events
- 30 May 2025 Drugs for Neglected Diseases plans a phase II trial for Cutaneous Leishmaniasis in Brazil and Panama in November 2025 (PO) (NCT06997159)
- 28 Apr 2025 Phase-II clinical trials in Chagas disease in Argentina, Colombia (PO) (NCT06632600)
- 07 Oct 2024 Novartis plans a phase II trial for Chagas disease (PO) in August 2025 (NCT06632600)